Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Randomized, Double-blinded Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® to Evaluate Lot-to-lot Consistency

NCT03365921 is registered in ClinicalTrials.gov with Xiamen Innovax Biotech Co., Ltd as lead sponsor.

NCT NCT03365921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03365921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Randomized, Double-blinded Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® to Evaluate Lot-to-lot Consistency
Lead sponsor
Xiamen Innovax Biotech Co., Ltd
Phase
Phase 4
Overall status
Completed
Start date
October 27, 2018
Completion date
June 16, 2019
Enrollment
360 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis e